Track record · closed signal

Merck & Company Inc (MRK) — closed signal from March 17, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 15, 2026 — -0.1% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$111.39 – $115.34Entry zone — fair-value band

$115.00Published — price the day we called it

$123.32Target — the price the thesis aimed for

$123.11Peak — highest point inside the window, not a realized return

$114.90Window close — end-of-window price, context only

What happened

Near target

Came within reach: 89% of the predicted growth at its peak, just short of the target.

At window close

-0.1%

realized, from the publication price to the last close inside the window

Peak gain

+7.1%

peak, from the publication price — not a realized return

S&P 500, same window

+12.8%

SPY over the identical days, dividend-adjusted

Window close

$114.90

last close inside the window, ended June 15, 2026

Peak price

$123.11

peak on April 9, 2026 — not a realized return

Days to target

—

The thesis — published March 17, 2026

Predicted growth

+8%

over the measurement window

Target price

$123.32

the price the thesis aimed for

Entry zone

$111.39 – $115.34

the fair-value band we waited for

Price at publication

$115.00

published March 17, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is being watched as a stable, defensive stock that might bounce back rather than a fast grower. New data about Gardasil and a higher analyst target make the shares look less beaten-up, but most upside is limited because investors worry one product contributes a lot of the companys value. In the next 0-3 months, the appeal is steadiness and a likely pullback toward normal levels rather than big gains.

Primary drivers

New Gardasil data suggests the vaccine remains strong and reliable
A higher analyst target helps short-term investor sentiment
Healthcare is defensive and can protect value in mixed markets
Muted recent trading makes a steady rebound more likely

How it played out

MRK: rebound came close, but the target was missed

Lyra published MRK at 115 with expected growth of 8% and a target of 123.32. The thesis expected a steady rebound rather than rapid growth. It pointed to new Gardasil data, a higher analyst target, healthcare's defensive role, and muted recent trading.

MRK reached 123.11 on April 9, a peak gain of 7.1%. It stayed below the target, so there was no time to target. The stock ended the window at 114.90. The rebound partially played out, but the published target was missed.

What happened during the window

On April 30, Merck reported first-quarter sales of $16.3 billion, up 5%. On May 5, the company completed its acquisition of Terns Pharmaceuticals.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals